IART · Nasdaq · Healthcare · Medical Devices
$14.41+0.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 23, 2026
Company outlook: revenue of $1.6B to $1.7B for Fiscal year 2026 — up 0.5% on a year earlier
The quarter ending September 30, 2026, against the same quarter a year earlier.
Integra Lifesciences Holdings Corp.’s own guidance, from its results release of October 21, 2026. It is the company’s statement of what it expects, not a forecast of ours.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $411.2M | $402.1M | +2.27% |
| Profit | $14.9M | -$5.4M | +374.83% |
| Profit per share | $0.19 | -$0.07 | +371.43% |
| Free Cash Flow | $85.7M | $25.8M | +232.94% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Integra Lifesciences Holdings Corp. has no earnings call transcript available.
“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Integra Lifesciences Holdings Corp.’s Item 2.02 8-K filed October 21, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.